CONVENIENCE FOR YOU AND YOUR PATIENTS

A complete regImen wIth a favourable DDI profIle¹

One pill, once a day. No time-of-day restrictions. Can be taking with or without food. Few significant drug-drug interactions.

DOVATO: A REGIMEN WITH A GENERALLY FAVOURABLE DRUG-DRUG INTERACTION PROFILE

DDIs Between EACS-Recommended or Alternative Regimens as Initial Therapy Available as a Single Pill and 43 Commonly Prescribed Non-ARVs as Defined by EACS²*

These pie charts show the potential drug-drug interactions between recommended and alternative EACS initial regimens available as a single pill and 43 commonly prescribed non-ARVs as defined by EACS. DOVATO has few significant drug-drug interactions.

*Includes 43 non-ARVs across cardiovascular drugs, CNS drugs, anti-infectives and miscellaneous (eg, antacids, PPIs, H2 blockers, methadone and St John’s wort) included in EACS Guidelines as commonly co-prescribed or of particular clinical relevance.2 Original data source: University of Liverpool drug interaction data.3

Contraindicated with fampridine.1,3

DOVATO DRUG-DRUG INTERACTIONS

  • Minimal effect on metabolism via the CYP3A4 pathway
     
  • No known interactions with contraceptives, antihypertensives, proton pump inhibitors, statins, PDE-5 inhibitors or recreational drugs
     
  • The recommended dose of dolutegravir is 50 mg twice daily when co-administered with rifampicin. As Dovato is a fixed-dose tablet, an additional 50 mg tablet of dolutegravir should be administered approximately 12 hours after Dovato for the duration of the rifampicin co-administration (a separate formulation of dolutegravir is available for this dose)
  • Contraindication with substrates of OCT-2 with narrow therapeutic windows, such as fampridine
     
  • Avoid chronic co-administration of sorbitol and similar solutions
     
  • The combination of Dovato with cladribine is not recommended
     
  • A dose adjustment of metformin should be considered when starting and stopping co‑administration of Dovato, to maintain glycaemic control. In patients with moderate renal impairment a dose adjustment of metformin should be considered when co-administered with Dovato, because of the increased risk for lactic acidosis in patients with moderate renal impairment due to increased metformin concentration
  • The recommended dose of dolutegravir is 50 mg twice daily when co-administered with rifampicin, oxcarbazepine, carbamazepine, phenytoin, phenobarbital, St John’s Wort, etravirine (without boosted protease inhibitors), efavirenz, nevirapine, tipranavir/ritonavir. As Dovato is a fixed-dose tablet, an additional 50 mg tablet of dolutegravir should be administered approximately 12 hours after Dovato for the duration of co-administration
     
  • Polyvalent cation-containing antacids are recommended to be taken 2 hours after or 6 hours before Dovato and should not be co-administered at the same time
     
  • Supplements or multivitamins containing calcium, iron or magnesium can be taken at the same time as Dovato when with food. When Dovato is taken without food, it is recommended that the supplement is taken 2 hours after or 6 hours before Dovato

 

References:

  1. Dovato (dolutegravir/lamivudine) Summary of Product Characteristics (SmPC)
  2. European AIDS Clinical Society. Guidelines. Version 10.1  https://www.eacsociety.org/files/guidelines-10.1.finalsept2020.pdf Accessed February 24, 2021
  3. University of Liverpool HIV interaction checker.  https://www.hiv-druginteractions.org/checker. Last accessed February 24, 2021

PM-GB-DLL-WCNT-210004 I April 2021